Press release
Atopic Dermatitis (Atopic Eczema) - Pipeline Review, H2 2018 - ResearchByMarkets.com
Atopic Dermatitis (Atopic Eczema) - Pipeline Review, H2 2018
Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.
Report Highlights
Atopic Dermatitis (Atopic Eczema) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Atopic Eczema) (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Atopic Dermatitis (Atopic Eczema) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis (Atopic Eczema) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 10, 42, 20, 1, 46, 14 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 4 and 2 molecules, respectively.
Atopic Dermatitis (Atopic Eczema) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
VIEW TOC AND LIST OF TABLES/FIGURES:
https://www.researchbymarkets.com/report/atopic-dermatitis-atopic-eczema-pipeline-review-h2-2018-32974.html
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Atopic Eczema) (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Atopic Eczema) (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atopic Dermatitis (Atopic Eczema) (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atopic Dermatitis (Atopic Eczema) (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Atopic Eczema) (Dermatology)
REQUEST A SAMPLE REPORT:
https://www.researchbymarkets.com/sample-request/32974
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Atopic Eczema) (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Atopic Eczema) (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned:
AbbVie Inc
Abeome Corp
Accolade Pharmaceuticals LLC
Aclaris Therapeutics Inc
Allergan Plc
Almirall SA
Amgen Inc
Amorepacific Corp
AnaptysBio Inc
AntibioTx AS
Asana BioSciences LLC
Aslan Pharmaceuticals Pte Ltd
Bausch Health Companies Inc
Bioleaders Corp
Blueberry Therapeutics Ltd
Celgene Corp
ChironWells GmbH
Chugai Pharmaceutical Co Ltd
Clevexel Pharma SAS
Cutanea Life Sciences Inc
Dermala Inc
DURECT Corp
Eli Lilly and Co
Evelo Biosciences Inc
Evotec AG
F. Hoffmann-La Roche Ltd
Fountain Biopharma Inc
Galapagos NV
Galderma SA
Galectin Therapeutics Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Golden Biotechnology Corp
Han Wha Pharma Co Ltd
Heptares Therapeutics Ltd
iCo Therapeutics Inc
Immune Pharmaceuticals Inc
Incyte Corp
Inflamalps SA
Innovation Pharmaceuticals Inc
Japan Tobacco Inc
JW Pharmaceutical Corp
Kang Stem Biotech Co Ltd
Kv1.3 Therapeutics
Kyowa Hakko Kirin Co Ltd
Lead Pharma Holding BV
LEO Pharma A/S
Madam Therapeutics BV
Medicenna Therapeutics Corp
MedImmune LLC
NeoPharm Co Ltd
NeuroCycle Therapeutics GmbH
Novan Inc
Novartis AG
Nuevolution AB
OliX Pharmaceuticals Inc
Orbis Biosciences Inc
Otsuka Holdings Co Ltd
Pfizer Inc
Pharmedartis GmbH
Portola Pharmaceuticals Inc
Provectus Biopharmaceuticals Inc
Qurient Co Ltd
Realm Therapeutics Plc
Regeneron Pharmaceuticals Inc
Ribomic Inc
Sienna Biopharmaceuticals Inc
Signum Biosciences Inc
Spherium Biomed SL
sterna biologicals Gmbh & Co KG
TaiwanJ Pharmaceuticals Co Ltd
The Geneva Biotech Center SA
Torrent Pharmaceuticals Ltd
VivaCell Biotechnology Espana SL
vTv Therapeutics Inc
XBiotech Inc
Xencor Inc
Zhejiang I-Biological Technology Co Ltd
Get in touch with us:
ResearchByMarkets.com
Ritesh Tiwari, Director
enquiry@researchbymarkets.com
USA: +1-800-416-3124
About Us:
"Research By Markets" is a Market Research Reports Depository. Our Latest Market Research Reports cover a lot of Industry Sectors - Aerospace and Defense, Automotive and Transportation, Chemicals and Materials, Consumer Goods and Services, Energy and Power, Environmental, Food and Beverages, Healthcare, Information Technology, Manufacturing and Construction, Medical Devices, Petroleum, Pharmaceuticals, Semiconductor and Electronics, Telecommunications and more.
We are trusted by Fortune 500 companies for our client centric support. We have helped our clients in procuring research studies as per their requirements and also ensured they get proper post purchase support. We ensure that all our client queries are addressed in quick time.
We strive our best to ensure that our clients have a seamless experience and are happy and smiling every time they do business with us.
https://www.researchbymarkets.com/aboutus
Research By Markets
E/3, Ganga Homes,
Behind Bank Of India,
Viman Nagar,
Pune 411 014.
Maharashtra, India
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Atopic Dermatitis (Atopic Eczema) - Pipeline Review, H2 2018 - ResearchByMarkets.com here
News-ID: 1210353 • Views: …
More Releases from Research By Markets
V2X (Vehicle-to-Everything) Communications Ecosystem expected to grow at a CAGR …
Commonly referred to as V2X, vehicle-to-everything communications technology allows vehicles to directly communicate with each other, roadside infrastructure, and other road users to deliver an array of benefits in the form of road safety, traffic efficiency, smart mobility, environmental sustainability, and driver convenience. In addition, V2X is also helping pave the way for fully autonomous driving through its unique non line-of-sight sensing capability which allows vehicles to detect potential hazards,…
Research By Markets - Trusted By Market Leaders
Research By Markets is a Market Research Reports Online Repository. We have a huge database of syndicated market research reports that are segmented by Industry Verticals mainly - Telecommunication, Semiconductor, Electronics, Information Technology, Automotive, Healthcare, Pharmaceutical, Medical Devices, Biotechnology, Energy, Power, Aerospace, Defense, Consumer Goods, Construction, Equipment and many more.
Our clientele includes Fortune listed companies who trust us to help them with their market intelligence requirements.
Research By Markets being a…
Global Veterinary Services Market: Size, Trends and Forecasts (2018-2022) - Rese …
The report titled "Global Veterinary Services Market: Size, Trends and Forecasts (2018-2022)", provides an in depth analysis of the global veterinary services market by value, by segments, by services, by region, etc. The report also provides a regional analysis of the veterinary services market, including the following regions: North America, Europe, Asia Pacific, Latin America and MEA.
The report also assesses the key opportunities in the market and outlines the factors…
Pancreatic and Bile Duct Cancer Drug Development Pipeline Review, 2018 - Researc …
Pancreatic and Bile Duct Cancer Drug Development Pipeline Review, 2018
Summary
This report provides an overview of the pipeline landscape for pancreatic and bile duct cancer. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for pancreatic and bile duct cancer, and features dormant and discontinued products.
Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas, a…
More Releases for Atopic
Atopic Dermatitis - Drug Pipeline Landscape, 2022
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may cr*ck and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness.
Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an…
Atopic Dermatitis (Atopic Eczema) Treatment Market Business Growth And Industry …
Precision Business Insights published a research report on “Atopic Dermatitis (Atopic Eczema) Treatment Market by Drug type (Corticosteroids, Calcineurin Inhibitors, Immunosuppressants, Phosphodiesterase type 4 (PDE-4) Inhibitors, Antibiotics, Antihistamines, Emollients), Route of administration (Oral, Topical, Parenteral), Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography - Global/Region/Country Forecast to 2027”.
In people who suffer from atopic dermatitis, allergies play a big influence. When the patient is exposed to…
Current research: Demand for Atopic Dermatitis Treatment Market rapidly growing …
Report Ocean released a report deciphering the Atopic Dermatitis Treatment Market report that provides in-depth analysis and crucial insights into key factors that are crucial to the success of the market.
The report is a systematic study of the market that provides key statistics on trends, analyst views, competitive landscapes, and key regions markets report is a comprehensive study. In this research report, key business trends and upcoming Atopic Dermatitis Treatment…
Atopic Dermatitis - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Atopic Dermatitis - Pipeline Review, H2 2017 to its growing collection of premium market research reports.
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis - Pipeline Review, H2 2017, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.
Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored…
Global Atopic Dermatitis (Atopic Eczema) Treatment Market: Market Estimation, Dy …
Atopic dermatitis is also known as atopic eczema. Atopic dermatitis is a type of inflammatory disease which is of unknown origin usually starts in early infancy, but also affects a major number of adults. Atopic dermatitis results in itchy, red, swollen and cracked skin. Many people with atopic dermatitis may develop hay fever and asthma. The causes are unknown but it is found to involve inherited, immune system dysfunction, environmental…
Europe Atopic Dermatitis Drugs Market Report 2017
This report studies sales (consumption) of Atopic Dermatitis Drugs in Europe market, especially in Germany, France, UK, Russia, Italy, Spain and Benelux, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering
LEO Pharma
Mylan
Valeant
Bayer HealthCare
Encore Dermatology
Fill the form for an exclusive sample of this report @ http://www.qyresearchreports.com/sample/sample.php?rep_id=1020128&type=E
Market Segment by Countries, this report splits Europe into several key Countries, with sales…
